Thursday, September 26, 2019 2:32:51 PM
AbbVie, Allergan rating change at Citi
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal. Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential.
Recent ABBV News
- Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM • PR Newswire (US) • 10/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 08:07:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2024 09:00:11 PM
- Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • InvestorsHub NewsWire • 10/02/2024 01:00:00 PM
- Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing • PR Newswire (US) • 10/02/2024 12:00:00 PM
- AbbVie to Host Third-Quarter 2024 Earnings Conference Call • PR Newswire (US) • 10/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2024 09:06:50 PM
- AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer • PR Newswire (US) • 09/27/2024 04:13:00 PM
- AbbVie et SpinUp encouragent l'innovation dans le secteur des sciences de la vie au Canada avec le lancement du Prix AbbVie des innovateurs en biotechnologies • PR Newswire (Canada) • 09/26/2024 12:00:00 PM
- AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease • PR Newswire (US) • 09/26/2024 12:00:00 PM
- AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award • PR Newswire (Canada) • 09/26/2024 12:00:00 PM
- New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement • PR Newswire (US) • 09/25/2024 11:00:00 AM
- Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns • PR Newswire (US) • 09/24/2024 12:00:00 PM
- AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer • PR Newswire (US) • 09/20/2024 11:32:00 AM
- Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China • PR Newswire (US) • 09/11/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 07:30:45 PM
- AbbVie reçoit l'approbation de Santé Canada pour l'emploi de CONSTELLA® (linaclotide) dans le traitement de la constipation fonctionnelle chez les enfants âgés de 6 à 17 ans • PR Newswire (Canada) • 09/10/2024 11:00:00 AM
- Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age • PR Newswire (Canada) • 09/10/2024 11:00:00 AM
- AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs • PR Newswire (US) • 09/09/2024 01:00:00 PM
- AbbVie Declares Quarterly Dividend • PR Newswire (US) • 09/06/2024 02:13:00 PM
- AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia • PR Newswire (Canada) • 09/04/2024 12:00:00 PM
- AbbVie reçoit une recommandation favorable de la part de l'Agence des médicaments du Canada pour le remboursement de VRAYLAR® (cariprazine) dans le traitement de la schizophrénie • PR Newswire (Canada) • 09/04/2024 12:00:00 PM
- AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases • PR Newswire (US) • 08/27/2024 12:15:00 PM
- SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator • PR Newswire (US) • 08/27/2024 12:05:00 PM
- European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma • PR Newswire (US) • 08/19/2024 06:05:00 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM